Schroers-Martin Joseph G, Advani Ranjana
Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):511-516. doi: 10.1182/hematology.2024000668.
The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphoma (cHL), in 2015 for maintenance after autologous transplantation in high-risk patients, and in 2018 for frontline therapy with doxorubicin, vinblastine, and dacarbazine for advanced stage cHL. Although the role of BV in cHL had been reasonably well-established, it is currently being challenged by the changing landscape of other highly effective novel agents, such as checkpoint inhibitor immunotherapies. In this review, we discuss the evolving role of BV in the management of cHL and ongoing studies attempting to define the optimal usage of this effective agent.
靶向CD30的抗体药物偶联物brentuximab vedotin（BV）于2011年获美国食品药品监督管理局（FDA）批准用于治疗复发的经典型霍奇金淋巴瘤（cHL），2015年批准用于高危患者自体移植后的维持治疗，2018年批准与多柔比星、长春碱和达卡巴嗪联合用于晚期cHL的一线治疗。尽管BV在cHL中的作用已得到相当充分的确立，但目前正受到其他高效新型药物（如检查点抑制剂免疫疗法）不断变化的格局的挑战。在本综述中，我们讨论了BV在cHL管理中的不断演变的作用以及正在进行的旨在确定这种有效药物最佳用法的研究。
